Browsing by Author "Holte, Espen (23024605700)"
Now showing 1 - 4 of 4
- Results Per Page
- Sort Options
- Some of the metrics are blocked by yourconsent settings
Publication Criteria for surveys: From the European Association of Cardiovascular Imaging Scientific Initiatives Committee(2019) ;Haugaa, Kristina H. (24733615600) ;Marsan, Nina Ajmone (23035780700) ;Cameli, Matteo (36906722500) ;D'Andrea, Antonello (55612687400) ;Dweck, Marc R. (12783691400) ;Carvalho, Ricardo Fontes (57210811139) ;Holte, Espen (23024605700) ;Manka, Robert (8839069800) ;Michalski, Blazej (14527627100) ;Podlesnikar, Tomaz (57188636569) ;Popescu, Bogdan A. (37005664700) ;Schulz-Menger, Jeanette (6701382131) ;Sitges, Marta (7006509888) ;Stankovic, Ivan (57197589922) ;Maurer, Gerald (55606327600)Edvardsen, Thor (6603263370)The European Association of Cardiovascular Imaging (EACVI) is committed to maintaining the highest standards of professional excellence in all aspects of cardiovascular imaging. The mission of the EACVI is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging with a particular focus on education, training, scientific initiatives, and research. The EACVI established the Scientific Initiatives Committee (SIC) in December 2018. This committee has responsibility for surveys among imagers, patients' surveys and surveys including data from clinical practice. The current document describes the aims of the EACVI SIC and the creation of the international EACVI survey network. This document summarizes the EACVI's standards for the survey questions and standards for writing the papers with the results of the surveys. These are in accordance with previous recommendations and were approved by the EACVI SIC and the EACVI Board in 2019. © 2019 Published on behalf of the European Society of Cardiology. All rights reserved. - Some of the metrics are blocked by yourconsent settings
Publication EACVI survey on investigations and imaging modalities in chronic coronary syndromes(2021) ;Bularga, Anda (57211591557) ;Saraste, Antti (6603934178) ;Fontes-Carvalho, Ricardo (23097322300) ;Holte, Espen (23024605700) ;Cameli, Matteo (36906722500) ;Michalski, Blazej (14527627100) ;Williams, Michelle C. (58084596300) ;Podlesnikar, Tomaz (57188636569) ;D'Andrea, Antonello (55612687400) ;Stankovic, Ivan (57197589922) ;Mills, Nicholas L. (58894726300) ;Manka, Robert (8839069800) ;Newby, David E. (57529298000) ;Schultz-Menger, Jeanette (57221405702) ;Haugaa, Kristina H. (24733615600)Dweck, Marc R. (12783691400)Aims: The European Association of Cardiovascular Imaging (EACVI) Scientific Initiatives Committee performed a global survey to evaluate current practice for the assessment and management of patients with suspected and confirmed chronic coronary syndromes. Methods and results: One-hundred and ten imaging centres from 37 countries across the world responded to the survey. Most non-invasive investigations for coronary artery disease were widely available, except cardiovascular magnetic resonance (available 40% centres). Coronary computed tomography angiography (CCTA) and nuclear scans were reported by a multi-disciplinary team in only a quarter of centres. In the initial assessment of patients presenting with chest pain, only 32% of respondents indicated that they rely on pre-test probability for selecting the optimal imaging test while 31% proceed directly to CCTA. In patients with established coronary artery disease and recurrent chest pain, respondents opted for stress echocardiography (27%) and nuclear stress perfusion scans (26%). In asymptomatic patients with coronary artery disease and an obstructive (>70%) right coronary artery stenosis, 58% of respondents were happy to pursue medical therapy without further testing or intervention. This proportion fell to 29% with left anterior descending artery stenosis and 1% with left main stem obstruction. In asymptomatic patients with evidence of moderate-to-severe myocardial ischaemia (15%), only 18% of respondents would continue medical therapy without further investigation. Conclusion: Despite guidelines recommendations pre-test probability is used to assess patients with suspected coronary artery in a minority of centres, one-third of centres moving directly to CCTA. Clinicians remain reticent to pursue a strategy of optimal medical therapy without further investigation or intervention in patients with controlled symptoms but obstructive coronary artery stenoses or myocardial ischaemia. © 2020 The Author(s) 2020. Published by Oxford University Press on behalf of the European Society of Cardiology. - Some of the metrics are blocked by yourconsent settings
Publication EACVI survey on the evaluation of left ventricular diastolic function(2021) ;Sitges, Marta (7006509888) ;Ajmone Marsan, Nina (23035780700) ;Cameli, Matteo (36906722500) ;D'Andrea, Antonello (55612687400) ;Carvalho, Ricardo Fontes (57210811139) ;Holte, Espen (23024605700) ;Michalski, Blazej (14527627100) ;Podlesnikar, Tomaz (57188636569) ;Popescu, Bogdan A (37005664700) ;Schulz-Menger, Jeanette (6701382131) ;Stankovic, Ivan (57197589922) ;Haugaa, Kristina H (24733615600)Dweck, Marc R (12783691400)Aims: The aim of this study is to analyse how current recommendations on left ventricular (LV) diastolic function assessment have been adopted. Identifying potential discrepancies between recommendations and everyday clinical practice would enable us to better understand and address the remaining challenges in this controversial and complex field. Methods and results: A total of 93 centres, mainly from tertiary care settings, responded to the survey. More than three-quarters (77%) of centres follow the 2016 ASE/EACVI recommendations for LV diastolic function evaluation in patients with preserved ejection fraction based upon e′, E/e′, tricuspid regurgitation velocity, and left atrial (LA) volume. These recommendations were generally preferred to the previous 2009 version. Many centres also consider strain assessments in the LV (48%) and left atrium (53%) as well as diastolic stress echocardiography (33%) to be useful as additional assessments of LV diastolic function. Echocardiographic assessments of LV diastolic function were used frequently to guide therapy in 72% of centres. Conclusion: There is widespread adoption of current recommendation on the evaluation of LV diastolic function and these are frequently used to guide patient management. Many centres now also consider LV and LA strain assessments useful in the clinical assessment of diastolic function. These may be considered in future recommendations. © 2021 The Author(s). - Some of the metrics are blocked by yourconsent settings
Publication The EACVI survey on cardiac imaging in cardio-oncology(2021) ;Stankovic, Ivan (57197589922) ;Dweck, Marc R (12783691400) ;Marsan, Nina Ajmone (23035780700) ;Bergler-Klein, Jutta (56019537300) ;Holte, Espen (23024605700) ;Manka, Robert (8839069800) ;Schulz-Menger, Jeanette (6701382131) ;Sitges, Marta (7006509888)Haugaa, Kristina H (24733615600)Early and late cardiovascular (CV) toxicities related to many cancer treatments may complicate the clinical course of patients, offsetting therapeutic benefits, and altering prognosis. The early detection, monitoring, and treatment of cardiotoxicity have therefore become essential parts of cancer patient care. CV imaging is a cornerstone of every cardio-oncology unit, but its use may vary across Europe because of the non-uniform availability of advanced imaging techniques and differences in the organization and logistics of cardio-oncology services. The purpose of this EACVI survey in cardio-oncology is to obtain real-world data on the current usage of cardiac imaging in cancer patients. Data from 104 centres and 35 different countries confirmed that cardiac imaging plays a pivotal role in the detection and monitoring of cardiac toxicity in oncology patients in Europe and beyond. However, it also revealed gaps between guidelines recommendations and everyday clinical practice, highlighting some of the challenges that need to be overcome in this rapidly advancing field. © 2020 Published on behalf of the European Society of Cardiology. All rights reserved.